About this episode

The episode discusses key hematologic oncology developments presented at the 2026 ASCO Annual Meeting.

In a live X Spaces discussion hosted by CancerNetwork® in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT), Marc J. Braunstein, MD, PhD, and Sofia Zahid, MD, highlighted noteworthy presentations and abstracts in hematologic oncology at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Together, they discussed the data that may shake up clinical practice across different multiple myeloma, leukemia, and lymphoma populations. Braunstein is an associate professor in the Department of Medicine and course co-director of the Hematology/Oncology System at NYU Grossman Long Island School of Medicine, as well as the fellowship program director of Hematology/Oncology at NYU Langone Health. Zahid is a first-year fellow at NYU Grossman Long Island School of Medicine. The discussion focused on the following abstracts: · Abstract 7512 o Combining belantamab mafodotin-blmf (Blenrep) with daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone produced rapid activity among patients with transplant-ineligible newly diagnosed multiple myeloma in the phase 1/2 BelaDRd study (EUCT-2024-515634-32). o The progression-free survival…

People in this episode

Host: CancerNetwork

Guests: Marc J. Braunstein, MD, PhD, Sofia Zahid, MD

Topics covered

• hematologic oncology
• ASCO 2026
• multiple myeloma
• leukemia
• lymphoma
• clinical practice

Keywords

• hematologic oncology
• ASCO 2026
• multiple myeloma
• leukemia
• lymphoma
• clinical practice
• Revumenib
• belantamab mafodotin-blmf

Mentioned in this episode

Organizations: American Society for Transplantation and Cellular Therapy, NYU Grossman Long Island School of Medicine, NYU Langone Health

Products: belantamab mafodotin-blmf, daratumumab, lenalidomide, dexamethasone, Revumenib

Explore listener stats, chart rankings, contacts and more on the Oncology On The Go podcast page.